





Queen Mary Bioenterprises Investment Forum

5th October 2011





Presenting Company Information

Session	Company	£ Sought	Logo
AM	<p>Genetic Micro Devices</p> <p>Over the past 4 years Genetic Microdevices developed an instrument that analyses biological samples such as proteins and DNA. The device is based on a disposable chip that performs analyses based on so-called molecular separations. The technology has a wide range of applications in drug development, personalised medicine and diagnostic tests. The separation market is worth around \$10bn annually.</p>	500k	
AM	<p>Stealthy Therapeutics</p> <p>Stealthy's Prothyx[®] drug delivery platform exploits the latency of TGF-β1 latency associated peptide (LAP) to confer improved clinical benefit to a range of biological drugs by (i) directing therapeutic activity only at the diseased tissue, (ii) minimising the adverse side effects on other tissues, (iii) increasing the therapeutic window where drugs can be used safely, and (iv) extending the re-administration interval for drugs that require regular dosing.</p>	500k	
AM	<p>Intelligent Ultrasound</p> <p>Intelligent Ultrasound, a medical imaging software company, has developed a software platform that improves image quality and field of view compared to traditional ultrasound scans. This technology has been demonstrated to increase significantly the percentage of patients who can be diagnosed using ultrasound.</p>	750k	
AM	<p>i2eye Diagnostics</p> <p>i2eye Diagnostics is commercialising a first to market eye care device that was developed at the University of Edinburgh Hospitals in response to a pressing clinical need in paediatric neurology and ophthalmology. There is an academic prototype instrument in clinical use. The company has an exclusive worldwide license to the IP and is being incubated by the Edinburgh BioQuarter.</p>	800k (two stage series A)	





Queen Mary Bioenterprises Investment Forum

5th October 2011

Presenting Company Information

AM	<p>UroSens</p> <p>UroSens is developing a new highly reliable, cheap and simple urine test to diagnose bladder and/or prostate cancer by measuring the amount of a protein biomarker called Mcm5 in urine. This biomarker was discovered and patented by Cancer Research (UK) and has been licensed to UroSens for diagnosing these cancers.</p>	500k	
AM	<p>Atlantic Healthcare</p> <p>Atlantic Healthcare has the worldwide exclusive rights to market a unique drug (alicaforfen) for Inflammatory Bowel Disease (IBD), a growing \$2bn global market. Developed by a leading US drug research company, \$75m has been spent on development and validation. The company, ISIS Pharmaceuticals Inc, acquired and retains a 12% stake in the company.</p>	1M	
PM	<p>Activiomics</p> <p>Activiomics has developed innovative technologies using mass spectrometry to interrogate and interpret the activity of cellular signalling pathways. Activiomics is partnering with the pharmaceutical and biotechnology industry to generate high value information using its novel TIQUAS platform. This has significant advantages over existing phosphoproteomics techniques.</p>	5M	
PM	<p>Altos Vision</p> <p>Altos Vision Ltd is a UK registered ophthalmology company. The lead product, AV 1, is for moderate to severe dry eye in post-menopausal women. Altos have reformulated AV 1 and filed a new patent that the IP attorney believes will obtain composition of matter approval. The Altos management team has over 50 years experience in developing and commercialising ophthalmology products, including high level involvement on five other dry eye products, including the only one to be approved by the FDA.</p>	2.8M	

Queen Mary Bioenterprises Investment Forum
5th October 2011
Presenting Company Information

PM	<p>Momentum Bioscience</p> <p>Momentum Bioscience is developing assays for rapid detection of bacterial and fungal infection (e.g. sepsis). Evaluations are taking place at Royal Hampshire County Hospital for a 3 hour test to detect the presence of blood infections (taking up to 3 days currently) and a 24 hour test for the absence of active infection (a 5 day process currently). The company has an IP, development and manufacturing partnership agreement with a US diagnostics company.</p>	2M	
PM	<p>Orthox</p> <p>Orthox is an oxford based medical device company, developing a pipeline of strong orthopaedic implants based on a tissue regenerative protein extracted from silk fibres. Through investment of ~£1.9m, Orthox has established manufacture and demonstrated preclinical validation of lead product, FibroFix™ Meniscus, a device for repair and regeneration of the meniscal cartilage in the knee.</p>	1M	
PM	<p>Aqix</p> <p>Aqix Limited is meeting the need for new products in the \$40bn intensive care and anaesthesia care therapeutics market. Aqix RS-I, the first product from its patented synthetic serum platform, is a treatment to reduce acute kidney injury (AKI) occurring during cardiac bypass surgery, which affects 30% of patients increasing costs by up to \$55,000. The company is led by a seasoned management team under Professor Vincent Lawton (ex MSD) and overseen scientifically by Professor Mythen of UCL, a key opinion leader.</p>	1.5M	
PM	<p>Progenitor Labs</p> <p>Progenitor Labs Ltd (Progenitor) is a start-up phase biotechnology venture spun off from Plasticell Ltd, one of the UK's pioneering stem cell biotech companies. Progenitor will exploit two proprietary high throughput stem cell technologies to discover novel small molecule drugs that act on adult stem/progenitor cells to regenerate the human body.</p>	5M	



Queen Mary Bioenterprises Investment Forum
5th October 2011
Presenting Company Information



Biotechnology Investment Forum

